Trial Profile
Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Everolimus (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2021 Status changed from active, no longer recruiting to completed.
- 07 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 07 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.